- GIST Tumors Linked to NF1 Mutations, Genetic Testing Needed
- KIT receptor and brain injury
- Marina comments on Phase I trials and DCC 2618
- most cancers have a greater dependency on changes in genes’ expression (80%) rather than on mutations (16%)
- New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs
- Recurrence-Free Survival in GIST at 90% with Long-Term Imatinib
- Reducing the Cost of Cancer Care: When Less is More
- Succinate dehydrogenase deficiency in a PDGFRA mutated GIST
- Trial Home Page